Jardiance (Cardinal Health)
Welcome to the PulseAid listing for the Jardiance drug offered from Cardinal Health. This Sodium-Glucose Cotransporter 2 Inhibitor [EPC],Sodium-Glucose Transporter 2 Inhibitors [MoA] pharmaceutical is classified as a HUMAN PRESCRIPTION DRUG. Below, you can view details for this drug, such as its dosage form, route of delivery, start market/end market dates, and more. We have also randomly listed additional pharmaceuticals used in the same HUMAN PRESCRIPTION DRUG drug type category.
LABELER NAME / MANUFACTURER: | Cardinal Health |
NON-PROPRIETARY NAME: | Empagliflozin |
SUBSTANCE NAME: | EMPAGLIFLOZIN |
TYPE: | HUMAN PRESCRIPTION DRUG |
PHARMA CLASS: | Sodium-Glucose Cotransporter 2 Inhibitor [EPC],Sodium-Glucose Transporter 2 Inhibitors [MoA] |
ROUTE: | ORAL |
DOSAGE FORM: | TABLET, FILM COATED |
MARKETING CATEGORY NAME: | NDA |
START MARKETING DATE: | 2014-08-01 |
END MARKETING DATE: | 0000-00-00 |
Jardiance HUMAN PRESCRIPTION DRUG Details:
Item Description | Jardiance from Cardinal Health |
LABELER NAME: | Cardinal Health |
DEA SCHEDULE: |
|
ACTIVE STRENGTH: | 10(mg/1) |
START MARKETING DATE: | 2014-08-01 |
END MARKETING DATE: | 0000-00-00 |
PRODUCT ID: | 55154-0411_5777b8a8-ada6-4950-8548-43a1de11f075 |
PRODUCT NDC: | 55154-0411 |
APPLICATION NUMBER: | NDA204629 |
Other EMPAGLIFLOZIN Pharmaceutical Manufacturers / Labelers: